✨ Free AI Report
Rocket Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Rocket Pharmaceuticals, Inc.
Company Research

Rocket Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Rocket Pharmaceuticals, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Clinical validation and regulatory progress offer upside potential, but execution risk and analyst disagreement warrant cautious approach to valuation. The company has achieved key regulatory milestones including FDA acceptance of a resubmitted BLA for KRESLADI with a PDUFA date of March 28, 2026, and agreement to resume the pivotal.

What is Rocket Pharmaceuticals, Inc.'s industry? Rocket Pharmaceuticals, Inc. (rocketpharma.com) operates in Biotechnology - Gene Therapy. AskCyborg classifies Rocket Pharmaceuticals, Inc. under Biotechnology - Gene Therapy in its company registry.

Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need. The company specializes in developing trans...

5/ 10Mixed

Cyborg Score thesis

Clinical validation and regulatory progress offer upside potential, but execution risk and analyst disagreement warrant cautious...

Read the full analyst-debate transcript →
Industry Biotechnology - Gene Therapy
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Rocket Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Rocket Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Rocket Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Rocket Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Rocket Pharmaceuticals, Inc. Overview

Pro stress-test →

Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need. The company specializes in developing transformative treatments for complex genetic conditions including cardiovascular and immunological diseases.

Strategic Profile

Pro stress-test →

Rocket's innovative multi-platform approach allows the company to design the optimal gene therapy for each indication, creating potentially transformative options. With $188.9 million in cash and investments as of December 31, 2025, the company is positioned to fund operations into Q2 2027 while advancing key pipeline programs including a near-term FDA decision on KRESLADI.

Competitive Landscape

Pro stress-test →

Rocket operates in the gene therapy space alongside competitors developing treatments for rare genetic disorders. The company differentiates through its multi-platform approach supporting both AAV and lentiviral programs, addressing cardiovascular and immunological indications where few alternatives exist.

Industry Context

Rocket Pharmaceuticals, Inc. operates in Biotechnology - Gene Therapy.

Key facts

Founded: 2011 · Headquarters: Cranbury, US · Employees: N/A · Revenue: N/A · Market cap: $490M-$544M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Rocket Pharmaceuticals, Inc..

  • FDA accepted KRESLADI BLA resubmission with PDUFA decision expected March 28, 2026
  • RP-A501 pivotal Phase 2 trial to resume in first half 2026 with ongoing FDA engagement for additional programs
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026FDA accepted KRESLADI BLA resubmission with March 28, 2026 PDUFA decision target
  • Feb 2026Reported Q4 and full-year 2025 results with improved cash position of $188.9M
  • +2 moreTrack every material event for Rocket Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Rocket Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Gene Therapy for Rare DiseasesGene therapy for hemophilia and other genetic disorders→Gene Therapy for Rare DiseasesAAV-based gene therapies for rare genetic diseases→Gene Therapy for Rare DiseasesGenetic and neurological disorder therapies→

Compare Rocket Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Rocket Pharmaceuticals, Inc. operates in Biotechnology - Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Gene Therapy research →
NEW · MCP server

Ask your AI assistant about Rocket Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Rocket Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Rocket Pharmaceuticals, Inc. do this quarter?”
“Is Rocket Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Rocket Pharmaceuticals, Inc. do?+
Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need. The company specializes in developing trans...
What is Rocket Pharmaceuticals, Inc.'s Cyborg Score?+
Rocket Pharmaceuticals, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Rocket Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Gene Therapy for Rare Diseases, Gene Therapy for Rare Diseases, Gene Therapy for Rare Diseases. The full competitive landscape is in the AskCyborg report.
How can I get the full Rocket Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Rocket Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Rocket Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Gene Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Neurogene Inc.7MeiraGTx Holdings plc7REGENXBIO Inc.64D Molecular Therapeutics, Inc.6Takara Bio Inc.6Voyager Therapeutics, Inc.5Rocket Pharmaceuticals, Inc.